---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-21-000142"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T14:07:18.670685+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evolent Q3 revenue $222.5M (-7.1% YoY); net loss $13M; board adds Dr. Tunde Sotunde

## Summary
- GAAP revenue $222.5M, down 7.1% YoY; revenue ex-divested assets up 36.3%.
- Net loss attributable to common $13.0M; Adjusted EBITDA $13.8M.
- Total lives managed 14.7M (1.6M EHS, 13.1M Clinical Solutions).
- New partnerships: Sunflower Medical Group, Northern Medical Group, Health New England; 10 partner additions in 2021.
- Board: Dr. Tunde Sotunde appointed; Frank Williams to non-executive Chairman effective Jan 1, 2022.

## SEC filing metadata
- accession: 0001628908-21-000142
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890821000142/0001628908-21-000142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890821000142/evh-20211028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-21-000142
- JSON: https://secwatch.observer/filing/0001628908-21-000142.json
- Plain text: https://secwatch.observer/filing/0001628908-21-000142.txt

## Key facts
- Executive change
  Frank Williams changed role as non-executive Chairman at Evolent Health, Inc..
  - Action: transition
  - Role: non-executive Chairman
  source text: Additionally, on October 28, 2021, the Board and Mr. Frank Williams mutually agreed that Mr. Williams will transition from Executive Chairman to the role of non-executive Chairman of the Board, effective January 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890821000142/0001628908-21-000142-index.htm
- Executive change
  Michael D’Amato retired as Director at Evolent Health, Inc..
  - Action: retired
  - Role: Director
  source text: On October 28, 2021, Mr. Michael D’Amato retired from the Company’s Board of Directors (the “ Board ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890821000142/0001628908-21-000142-index.htm
- Executive change
  Dr. Tunde Sotunde was appointed as Director at Evolent Health, Inc..
  - Action: appointed
  - Role: Director
  source text: On October 28, 2021, the Board (1) appointed Dr. Tunde Sotunde to the Board as a Class II director with a term expiring at the 2023 Annual Meeting and (2) appointed Dr. Sotunde to the Audit Committee of the Board and the Compliance and Regulatory Affairs Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890821000142/0001628908-21-000142-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.